English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Cytoreductive nephrectomy (CN) combined with cytokine therapy was once the standard of care for metastatic renal cell carcinoma (mRCC) (1,2). In the past decade, there have been a myriad of novel therapies in metastatic renal cell carcinoma treatments including targeted therapies such as tyrosine kinase inhibitors (TKIs), mammalian target or rapamycin (mTOR) inhibitors, VEGF inhibitors, and PD-1 inhibitors.

Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus—trends and effect on overall survival